Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) Non Operating Investment Income (2020 - 2026)

Opus Genetics has reported Non Operating Investment Income over the past 6 years, most recently at -$51.4 million for Q1 2026.

  • Quarterly Non Operating Investment Income fell 1931.16% to -$51.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$65.7 million through Mar 2026, down 2383.07% year-over-year, with the annual reading at -$11.5 million for FY2025, 16093.06% down from the prior year.
  • Non Operating Investment Income was -$51.4 million for Q1 2026 at Opus Genetics, down from -$5.7 million in the prior quarter.
  • Over five years, Non Operating Investment Income peaked at $2.8 million in Q1 2025 and troughed at -$51.4 million in Q1 2026.
  • The 4-year median for Non Operating Investment Income is $40000.0 (2023), against an average of -$7.8 million.
  • Year-over-year, Non Operating Investment Income skyrocketed 278.95% in 2024 and then crashed 8033.33% in 2025.
  • A 4-year view of Non Operating Investment Income shows it stood at $19000.0 in 2023, then skyrocketed by 278.95% to $72000.0 in 2024, then crashed by 8033.33% to -$5.7 million in 2025, then crashed by 799.23% to -$51.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Non Operating Investment Income are -$51.4 million (Q1 2026), -$5.7 million (Q4 2025), and -$9.5 million (Q3 2025).